ArticleCancer medicine2023

First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.

Guangjian Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.